ArticleMolecular carcinogenesis2026
The FOXQ1/SSBP2 Regulatory Axis Drives Malignant Progression of Melanoma.
Article in Molecular carcinogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The FOXQ1/SSBP2 Regulatory Axis Drives Malignant Progression of Melanoma.Molecular carcinogenesis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Melanoma is a highly aggressive skin cancer with poor prognosis, often linked to excessive UV exposure. Despite advancements in immunotherapy and targeted treatments, melanoma's invasiveness and metastatic potential remain significant challenges. This study aimed to identify novel molecular targets associated with melanoma progression. Consensus clustering analysis revealed three melanoma subtypes, with the C3 subtype exhibiting the worst prognosis. Weighted gene co-expression network analysis (WGCNA) identified FOXQ1 as a key driver in this subtype. FOXQ1 expression was elevated in clinical melanoma tissues and cell lines, and silencing FOXQ1 in vitro reduced melanoma cell proliferation, migration, and induced apoptosis. To explore its downstream targets, FOXQ1 was found to repress the expression of SSBP2, a gene inversely correlated with FOXQ1. Functional assays demonstrated that silencing SSBP2 promoted melanoma malignancy. Rescue experiments showed that knockdown of SSBP2 reversed the tumor-suppressive effects of FOXQ1 silencing. These results suggest that the FOXQ1/SSBP2 regulatory axis plays a critical role in melanoma progression and may serve as a potential therapeutic target to improve melanoma treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.